Survival trends and long-term toxicity in pediatric patients with osteosarcoma

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Hagleitner, Melanie M ^a   De Bont, Eveline S J M ^b   Te Loo, D Maroeska W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLINIC ACID; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW DEPRESSION; BRAIN DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OSTEOSARCOMA; OTOTOXICITY; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE;

EID: 84871645402     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/636405     Document Type: Article

References (26)

1. Bacci G., Picci P., Ferrari S., Primary chemotherap and deleyed surgery for nonmetastatic osteosarcom of the extremities: results in 164 patients preoperatively treates with high doses of methotrexate followed by cisplatin and doxorubin. Cancer 1993 72 3227 3230
2. Bielack S. S., Carrle D., Hardes J., Schuck A., Paulussen M., Bone tumors in adolescents and young adults. Current Treatment Options in Oncology 2008 9 1 67 80 2-s2.0-47049131487 10.1007/s11864-008-0057-1
3. Eselgrim M., Grunert H., Kühne T., Zoubek A., Kevric M., Bürger H., Jürgens H., Mayer-Steinacker R., Gosheger G., Bielack S. S., Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatric Blood and Cancer 2006 47 1 42 50 2-s2.0-33646889372 10.1002/pbc.20608
4. Lewis I. J., Weeden S., Machin D., Stark D., Craft A. W., Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. Journal of Clinical Oncology 2000 18 24 4028 4037 2-s2.0-0034671187
5. Bacci G., Forni C., Ferrari S., Longhi A., Bertoni F., Mercuri M., Donati D., Capanna R., Bernini G., Briccoli A., Setola E., Versari M., Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. Journal of Pediatric Hematology/Oncology 2003 25 11 845 853 2-s2.0-0242693234 10.1097/00043426-200311000-00006
6. Ferrari S., Palmerini E., Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Current Opinion in Oncology 2007 19 4 341 346 2-s2.0-34249999670 10.1097/CCO.0b013e328122d73f
7. Bacci G., Ferrari S., Bertoni F., Ruggieri P., Picci P., Longhi A., Casadei R., Fabbri N., Forni C., Versari M., Campanacci M., Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. Journal of Clinical Oncology 2000 18 24 4016 4027 2-s2.0-0034671416
8. Kaplan E. L., Meier P., Nonparametric observations from incomplete observations. Journal of the American Statistical Association 1958 53 457 481
9. Gray R. J., A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics 1988 16 1141 1154
10. Kimball T. R., Michelfelder E. C., Echocardiography, in Moss & Adams's 'Heart Disease in Infants, Children, and Adolescents' 2008 8th Philadelphia, Pa, USA Lippincott Williams & Wilkins
11. Brock P. R., Bellman S. C., Yeomans E. C., Pinkerton C. R., Pritchard J., Cisplatin ototoxicity in children: a practical grading system. Medical and Pediatric Oncology 1991 19 4 295 300 2-s2.0-0025864140
12. Bielack S. S., Kempf-Bielack B., Delling G., Exner G. U., Flege S., Helmke K., Kotz R., Salzer-Kuntschik M., Wemer M., Winkelmann W., Zoubek A., Jürgens H., Winkler K., Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology 2002 20 3 776 790 2-s2.0-0036467661 10.1200/JCO.20.3.776
13. Nagarajan R., Kamruzzaman A., Ness K. K., Marchese V. G., Sklar C., Mertens A., Yasui Y., Robison L. L., Marina N., Twenty years of follow-up of survivors of childhood osteosarcoma. Cancer 2011 117 3 625 634 2-s2.0-79251494461 10.1002/cncr.25446
14. Delepine N., Delepine G., Jasmin C., Desbois J. C., Cornille H., Mathe G., Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. Biomedicine and Pharmacotherapy 1988 42 4 257 262 2-s2.0-0023822281
15. Bacci G., Ferrari S., Delepine N., Bertoni F., Picci P., Mercuri M., Bacchini P., Brach Del Prever A., Tienghi A., Comandone A., Campanacci M., Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. Journal of Clinical Oncology 1998 16 2 658 663 2-s2.0-0031943038
16. Graf N., Winkler K., Betlemovic M., Fuchs N., Bode U., Methotrexate pharmacokinetics and prognosis in osteosarcoma. Journal of Clinical Oncology 1994 12 7 1443 1451 2-s2.0-0028360590
17. van Dalen E. C., van As J. W., de Camargo B., Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database of Systematic Reviews 2011 5 CD006325 2-s2.0-79959515315
18. Pratt C. B., Meyer W. H., Luo X., Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer 1997 80 960 965
19. Aung L., Gorlick R. G., Shi W., Thaler H., Shorter N. A., Healey J. H., Huvos A. G., Meyers P. A., Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center experience. Cancer 2002 95 8 1728 1734 2-s2.0-0037108181 10.1002/cncr.10861
20. Neglia J. P., Friedman D. L., Yasui Y., Mertens A. C., Hammond S., Stovall M., Donaldson S. S., Meadows A. T., Robison L. L., Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. Journal of the National Cancer Institute 2001 93 8 618 629 2-s2.0-0035906222
21. Lipshultz S. E., Sanders S. P., Goorin A. M., Krischer J. P., Sallan S. E., Colan S. D., Monitoring for anthracycline cardiotoxicity. Pediatrics 1994 93 3 433 437 2-s2.0-0028125810
22. Steinherz L. J., Steinherz P. G., Tan C. T. C., Heller G., Murphy M. L., Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Journal of the American Medical Association 1991 266 12 1672 1677 2-s2.0-0025850827 10.1001/jama.266.12.1672
23. Stavroulaki P., Apostolopoulos N., Segas J., Tsakanikos M., Adamopoulos G., Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children. International Journal of Pediatric Otorhinolaryngology 2001 59 1 47 57 2-s2.0-0035978766 10.1016/S0165-5876(01)00455-4
24. Li Y., Womer R. B., Silber J. H., Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. European Journal of Cancer 2004 40 16 2445 2451 2-s2.0-7044260303 10.1016/j.ejca.2003.08.009
25. Pui C. H., Gajjar A. J., Kane J. R., Challenging issues in pediatric oncology. Nature Reviews Clinical Oncology 2011 8 540 549
26. Lanvers-Kaminsky C., Krefeld B., Dinnesen A. G., Deuster D., Seifert E., Würthwein G., Jaehde U., Pieck A. C., Boos J., Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatric Blood and Cancer 2006 47 2 183 193 2-s2.0-33745766865 10.1002/pbc.20673